Want to see LIVN full AI Analyst Report?
Top Page
LivaNova
(NASDAQ:LIVN)
Select Model
Select Model
Rating:71Outperform
Price Target:
$87.00
▲(29.62% Upside)
Action:Reiterated
Date:06/12/26
The score reflects improving fundamentals and a strong, guidance-upgraded earnings outlook, reinforced by a clear technical uptrend. These positives are tempered by a high valuation (P/E ~40), historical earnings volatility, and near-term free-cash-flow pressure tied to higher investment and working capital.
Positive Factors
Cardiopulmonary momentum & manufacturing scale
Greater Essenz penetration and planned manufacturing expansion support durable, recurring consumables pull-through tied to cardiac procedures. Market-share gains in HLM placements and higher output capacity reduce supply constraints, underpin sustainable revenue and margin expansion in cardiopulmonary over the medium term.
Negative Factors
Earnings volatility
Large swings in annual profitability indicate sensitivity to one-time items, reimbursement shifts and operational execution. Persistent volatility hampers forecasting, makes capital allocation harder, and can undermine investor and counterparty confidence if repeated, raising the risk profile over multiple reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Cardiopulmonary momentum & manufacturing scale
Greater Essenz penetration and planned manufacturing expansion support durable, recurring consumables pull-through tied to cardiac procedures. Market-share gains in HLM placements and higher output capacity reduce supply constraints, underpin sustainable revenue and margin expansion in cardiopulmonary over the medium term.
Read all positive factors
LivaNova (LIVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.56B
Dividend YieldN/A
Average Volume (3M)743.38K
Price to Earnings (P/E)40.2
Beta (1Y)0.98
Revenue Growth12.40%
EPS GrowthN/A
CountryUS
Employees3,300
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.97
Shares Outstanding54,933,537
10 Day Avg. Volume548,511
30 Day Avg. Volume743,377
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.79
Price to Sales (P/S)2.42
P/FCF Ratio19.36
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit4.24
Enterprise Value/Ebitda19.04
Forecast
1Y Price Target
$82.50Price Target Upside22.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)4.25
Revenue Forecast (FY)$1.51B
LivaNova Business Overview & Revenue Model
Company Description
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products...
How the Company Makes Money
LivaNova makes money primarily by selling medical devices and the recurring consumables and services associated with their use, with revenue generally recognized at the time products are delivered (subject to customer terms) and over time for cert...
LivaNova Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call delivered multiple material positive developments: double-digit Q1 revenue growth, upward revisions to full-year revenue and EPS guidance, regulatory approval and robust clinical evidence in OSA, meaningful reimbursement improvement for VNS in the U.S., strong cardiopulmonary momentum (Essenz upgrade and manufacturing expansion) and clinical differentiation (PolySync). Headwinds exist—near-term cash and free cash flow pressures driven by higher capex, working capital and a one-time bonus payout; modest gross margin compression; ongoing third-party supply constraints and reimbursement/coding uncertainty for HGNS and DTTD—which the company is actively addressing. On balance, the positives (revenue/earnings upgrades, regulatory/clinical milestones, market share gains and manufacturing expansion plans) outweigh the lowlights, indicating strong operational momentum while the company invests for growth and manages known near-term pressures.Positive Updates
Top-line Growth and Upgraded 2026 Revenue Guidance
Consolidated revenue of $362 million in Q1 2026, up 11% year-over-year on a constant currency basis; updated full-year 2026 revenue growth guidance increased to 7%–8% from 6%–7%.
Negative Updates
Adjusted Free Cash Flow and Cash Decrease in Q1
Adjusted free cash flow of $4 million in Q1 2026 versus $20 million in Q1 2025; cash decreased to $540 million from $636 million at year-end 2025, driven by early debt repayment, higher capital spend and working capital build.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-line Growth and Upgraded 2026 Revenue Guidance
Consolidated revenue of $362 million in Q1 2026, up 11% year-over-year on a constant currency basis; updated full-year 2026 revenue growth guidance increased to 7%–8% from 6%–7%.
Read all positive updates
Company Guidance
LivaNova raised full‑year 2026 revenue guidance to +7% to +8% on a constant‑currency basis (up from 6%–7%) with an estimated ~1% FX tailwind, while forecasting cardiopulmonary revenue growth of 8.5%–9.5% (up from 7%–8%) and epilepsy revenue growth of 6%–7% (up from 5.5%–6.5%); Q1 revenue was $362M, up 11% CC, including $209M in cardiopulmonary (+14%) and epilepsy up 8%. Key margin and profit targets include adjusted operating margin of 20%–21%, an adjusted effective tax rate of ~23%, and adjusted diluted EPS of $4.20–$4.30 (≈9% growth at midpoint) on ~56M diluted shares; adjusted free cash flow is still expected to be $160M–$180M, which includes $120M of capex (a $40M increase vs. prior year). Q1 highlights and liquidity: adjusted operating income was $71M, adjusted EPS $0.98, adjusted gross margin 68%, adjusted R&D $47M (13% of revenue), adjusted SG&A $129M (36%), Q1 adjusted FCF $4M, cash $540M and total debt $288M; company also expects cardiopulmonary manufacturing output to increase low double digits (new line in 2H26), Essenz to represent ~80% of HLM placements in 2026 (vs. 55% in 2025), a tariff net impact of <$5M on adjusted operating income, and an estimated ~$5M full‑year adverse impact from the Middle East conflict.LivaNova Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
73
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.43B | 1.39B | 1.25B | 1.15B | 1.02B | 1.04B |
| Gross Profit | 968.51M | 939.90M | 870.87M | 771.25M | 707.23M | 705.99M |
| EBITDA | 215.65M | -129.50M | 202.52M | 38.48M | 30.90M | -6.33M |
| Net Income | 107.14M | -242.50M | 63.23M | 17.55M | -86.25M | -135.82M |
Balance Sheet | ||||||
| Total Assets | 2.52B | 2.61B | 2.51B | 2.43B | 2.29B | 2.20B |
| Cash, Cash Equivalents and Short-Term Investments | 539.70M | 635.60M | 428.86M | 266.50M | 214.17M | 207.99M |
| Total Debt | 334.50M | 473.30M | 676.77M | 640.40M | 580.43M | 286.70M |
| Total Liabilities | 1.30B | 1.41B | 1.19B | 1.15B | 1.09B | 906.31M |
| Stockholders Equity | 1.21B | 1.20B | 1.32B | 1.28B | 1.21B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | 161.08M | 173.20M | 135.93M | 39.93M | 43.40M | 77.07M |
| Operating Cash Flow | 245.59M | 254.30M | 183.04M | 74.91M | 69.90M | 102.54M |
| Investing Cash Flow | -76.86M | -72.90M | -48.16M | -40.33M | -38.40M | 36.90M |
| Financing Cash Flow | -375.48M | -285.70M | 18.55M | 21.48M | 280.10M | -181.48M |
LivaNova Technical Analysis
Neutral
67.12
Price Trends
75.72
Positive
70.02
Positive
64.65
Positive
Market Momentum
1.82
Positive
47.43
Neutral
33.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIVN, the sentiment is Neutral. The current price of 67.12 is below the 20-day moving average (MA) of 81.33, below the 50-day MA of 75.72, and above the 200-day MA of 64.65, indicating a neutral trend. The MACD of 1.82 indicates Positive momentum. The RSI at 47.43 is Neutral, neither overbought nor oversold. The STOCH value of 33.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LIVN.
LivaNova Risk Analysis
LivaNova disclosed 34 risk factors in its most recent earnings report. LivaNova reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LivaNova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $1.84B | 25.86 | 16.61% | ― | 11.19% | 7.61% | |
71 Outperform | $4.56B | 40.16 | 9.13% | ― | 12.40% | ― | |
69 Neutral | $2.62B | 14.83 | 41.92% | ― | 30.24% | 244.83% | |
61 Neutral | $3.27B | 22.98 | 8.23% | ― | 5.48% | 77.43% | |
61 Neutral | $1.48B | 10.85 | 17.98% | ― | 8.94% | 102.92% | |
54 Neutral | $1.17B | 92.26 | 2.66% | ― | 17.59% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LIVN
LivaNova
79.12
36.13
84.04%
AORT
Artivion
23.13
-8.36
-26.55%
ITGR
Integer Holdings
93.31
-23.82
-20.34%
UFPT
Ufp Technologies
230.11
1.43
0.63%
INSP
Inspire Medical Systems
49.15
-78.35
-61.45%
TMDX
TransMedics Group
74.59
-38.73
-34.18%
LivaNova Corporate Events
Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial DisclosuresShareholder Meetings
LivaNova Shareholders Back 2026 AGM Proposals and Governance
Positive
Jun 11, 2026
LivaNova PLC held its 2026 Annual General Meeting of Shareholders on June 10, 2026, where investors approved the election of eleven directors for terms expiring at the 2027 AGM and endorsed the company’s U.S. and UK executive compensation re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.